A new study reveals that individuals with allergic rhinitis and asthma have distinct nasal fungal profiles, hinting at ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
Discover how a newly recommended immunotherapy works by gradually increasing the body’s resistance to house dust mites.
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Acarizax (12 ...
The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...
Thousands of people with a severe dust mite allergy could benefit from a "life changing" new daily treatment. The National ...
The NHS will now offer immunotherapy pill Acarizax so the body can become less sensitive to dust mites over time and halt ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ...
The treatment, known as 12 SQ-HDM SLIT, will help with the allergy which can be debilitating and cause facial swelling, ...
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results